25 April 2019 - - US-based clinical-stage biotechnology company Magenta Therapeutics (NASDAQ: MGTA) has dosed the first subjects in a Phase 1 study of MGTA-145, the company said.

Magenta intends to develop MGTA-145 in autoimmune diseases, blood cancers and genetic diseases.

More than 85% of the 65,000 transplants in the US and Europe each year use mobilized hematopoietic stem cells as a cell source.

MGTA-145 is a biologic chemokine factor that Magenta is developing as a first-line therapy for stem cell mobilization.

MGTA-145 is designed to enable single-day mobilization and collection of high numbers of stem cells without G-CSF, the current standard of care. MGTA-145 works synergistically with plerixafor, another stem cell mobilization product.

The Phase 1 study will investigate the safety and tolerability of MGTA-145 alone and in combination with plerixafor in healthy volunteers and establish recommended Phase 2 doses.

The study will also measure the number of hematopoietic stem cells in the blood after dosing with MGTA-145 alone and in combination with plerixafor.